SCHEMBL2831869

SCHEMBL2831869

CSCCn1c(C)c(C(=O)O)c2ccccc2c1=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ATM Q13315 3/20 0.41
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 2/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
TSHR P16473 3/20 0.37
HTT P42858 1/20 0.37
RECQL P46063 1/20 0.37
PARP1 P09874 1/20 0.37
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834290 0.84 MEN1 (0.49) MAPTMEN1KMT2AATMALDH1A1
SCHEMBL2830643 0.82 TDP1 (0.62) MEN1KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL2832041 0.81 ALDH1A1 (0.52) MAPTMEN1KMT2AATMALDH1A1
SCHEMBL2835070 0.81 L3MBTL1 (0.56) MEN1KMT2AALDH1A1TDP1L3MBTL1
SCHEMBL2834167 0.81 ALDH1A1 (0.63) MAPTMEN1KMT2AATMALDH1A1
SCHEMBL2149574 0.79 TACR3 (0.48) MEN1KMT2AATMALDH1A1SMN1; SMN2
SCHEMBL2831355 0.78 ALDH1A1 (0.65) MAPTMEN1KMT2AATMALDH1A1
SCHEMBL3350444 0.78 SMN1; SMN2 (0.58) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2832378 0.76 MEN1 (0.49) MAPTMEN1KMT2AATMALDH1A1
SCHEMBL2837392 0.76 MEN1 (0.42) MAPTMEN1KMT2AATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP claimed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US claimed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US claimed
WO-2010028655-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-18 WO claimed
CN-102149685-B Isoquinolinone derivatives as NK3 antagonists LUNDBECK & CO AS H 2015-01-07 CN disclosed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 MAPT 1473/4885MEN1 2461/4885KMT2A 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.